Brief: Karolinska Development's Umecrine Cognition Presents Preclinical Data On Golexanolone

Kdventures AB

11/01/2022 13:33

Jan 11 (Reuters) - Karolinska Development AB  KDEV.ST :
    * KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY UMECRINE
COGNITION
PRESENTS PRECLINICAL DATA SHOWING THAT GOLEXANOLONE REDUCES
NEUROINFLAMMATION AND COUNTERACTS MOTOR SYMPTOMS
    * RESULTS INDICATE THAT HARMFUL NEUROINFLAMMATION AND
DISEASE-RELATED MOTOR SYMPTOMS COULD BE ALLEVIATED BY CORRECTING
GABAA RECEPTOR ACTIVITY WITH GOLEXANOLONE.

Source text for Eikon:  ID:nGNE5VTJ7T 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))